The TRAF2-p62 axis promotes proliferation and survival of liver cancer by activating mTORC1 pathway

• Published in: Cell death and differentiation 2023-06, Vol.30 (6), p.1550-1562
• Main Authors: Liang, Xue, Yao, Jiping, Cui, Danrui, Zheng, Weiyang, Liu, Yanning, Lou, Guohua, Ye, Bingjue, Shui, Liyan, Sun, Yi, Zhao, Yongchao, Zheng, Min
• Format: Article
• Language: English
• Subjects: 13/105; 13/109; 13/89; 13/95; 14/34; 14/35; 631/337/474/582; 631/80/474/2073; 64/60; 82/51; 82/58; 82/80; 96/1; Adaptor proteins; Apoptosis; Biochemistry; Biomedical and Life Sciences; Cell Biology; Cell Cycle Analysis; Hepatocytes; Immunoprecipitation; Life Sciences; Liver cancer; Localization; Medical prognosis; NF-κB protein; Proteins; Proteomics; Stem Cells; TRAF2 protein; Tumor cell lines; Ubiquitin; Ubiquitin-protein ligase
• ISSN: 1350-9047; 1476-5403
• DOI: 10.1038/s41418-023-01164-7

TRAF2 (Tumor necrosis factor receptor-associated factor 2) is a dual function protein, acting as an adaptor protein and a ubiquitin E3 ligase, which plays an essential role in mediating the TNFα-NFκB signal pathway. Dysregulated expression of TRAF2 has been reported in a variety of human cancers. Whether and how TRAF2 regulates the growth of liver cancer cells remains elusive. The goal of this study is to investigate potential dysregulation of TRAF2 and its biological function in liver cancer, and to elucidate the underlying mechanism, leading to validation of TRAF2 as an attractive liver cancer target. Here, we reported TRAF2 is up-regulated in human liver cancer cell lines and tissues, and high TRAF2 expression is associated with a poor prognosis of HCC patients. Proteomics profiling along with Co-immunoprecipitation analysis revealed that p62 is a new substrate of TRAF2, which is subjected to TRAF2-induced polyubiquitination via the K63 linkage at the K420 residue. A strong negative correlation was found between the protein levels of p62 and TRAF2 in human HCC samples. TRAF2 depletion inhibited growth and survival of liver cancer cells both in vitro and in vivo by causing p62 accumulation, which is partially rescued by simultaneous p62 knockdown. Mechanistically, TRAF2-mediated p62 polyubiquitylation activates the mTORC1 by forming the p62-mTORC1-Rag complex, which facilitates the lysosome localization of mTORC1. TRAF2 depletion inhibited mTORC1 activity through the disruption of interaction between p62 and the mTORC1 complex. In conclusion, our study provides the proof-of-concept evidence that TRAF2 is a valid target for liver cancer.